Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Triptans

The Therapeutic Goods Administration (TGA) conducted a public consultation seeking comments from interested parties on changes to current requirements for advisory statements for labels of non-prescription medicines containing triptans (sumatriptan, zolmitriptan, rizatriptan, eletriptan), as included in the Required Advisory Statements for Medicine Labels (RASML) document.

For more information please visit consultation hub.

The consultation opened on Friday 6 August 2021. Interested parties responded by close of business, Friday 17 September 2021.

Consultation outcomes

Information on submissions received and the outcomes of the consultation are available from the consultation hub.